Transipeg

Quick links to important sections

Transipeg

Selected form

Method of action: Laxative

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Transipeg

What is Transipeg?

Transipeg is an osmotic laxative used for the symptomatic treatment of constipation in adults. It belongs to a group of medications designed to facilitate bowel movements by increasing the water content in the digestive tract.

Composition and Mechanism

The primary active ingredient in Transipeg is Macrogol 3350, a high molecular weight polymer. Unlike some other treatments, it is not absorbed into the bloodstream but remains within the intestinal lumen.

Its function is based on its ability to bind with water molecules. By retaining water in the stool, it helps to:

  • Soften the stool consistency.
  • Increase the volume of intestinal contents.
  • Stimulate the natural movement of the bowels (peristalsis).

Electrolyte Balance

In addition to the active polymer, Transipeg contains specific electrolytes, including sodium chloride, sodium sulfate, potassium chloride, and sodium bicarbonate. These components are included to help maintain the body's mineral balance while the medication works to promote hydration within the colon. This formulation is designed to minimize the risk of electrolyte disturbances during the treatment of constipation.

Regulatory References

  1. NIH MedlinePlus

What side effects are possible with Transipeg?

Possible side effects and safety information

The safety profile of Transipeg (Macrogol 3350 with electrolytes) is primarily defined by its mechanical, non-systemic action within the gastrointestinal tract, as documented in official regulatory sources. The most frequently observed adverse reactions are generally localized to the digestive system and are often dose-dependent.


Frequency Classification of Adverse Reactions

Adverse reactions are officially categorized by frequency based on clinical data:

Frequency Category Associated Adverse Reactions (Examples)
Very Common Diarrhoea
Common Abdominal pain, abdominal distension, flatulence, nausea, vomiting
Uncommon Pruritus (itching), urticaria, erythema (skin redness)
Very Rare Anaphylactic reaction, angioedema

These effects are grouped primarily under Gastrointestinal Disorders and Immune System Disorders in regulatory labeling. Mild diarrhoea, which is classified as Very Common, often responds to a reduction in the daily intake, consistent with the compound's osmotic mechanism.


Serious Adverse Reactions and Safety Constraints

The regulatory profile documents the potential for serious, low-frequency events, including Anaphylactic reaction and Angioedema, which constitute severe hypersensitivity responses.

Official labeling mandates specific safety constraints, restricting the use of this medicine in patients with underlying severe gastrointestinal pathologies. This includes known or suspected gastrointestinal obstruction or perforation, and severe inflammatory bowel conditions such as toxic megacolon or ileus. For patients with renal or hepatic impairment, caution is noted regarding the potential for water-electrolyte balance disorders, particularly if severe diarrhoea is experienced.

Overdose and Emergency Response

Overdose and when to seek help

The Transipeg overdose profile is defined by the consequences of severe fluid loss resulting from its osmotic action. Initial signs of overdose documented in regulatory sources include excessive diarrhea and thirst, which can advance to confusion or significant abdominal distension.


Severe Outcomes and Emergency Action

Official labeling warns that excessive fluid and electrolyte loss can lead to life-threatening systemic complications.

Classification Manifestation or Action
Severe Outcomes Cardiac arrhythmias, seizures, and severe fluid and electrolyte abnormalities (such as hyponatremia) are documented adverse events resulting from metabolic imbalance.
Immediate Action Seek immediate medical attention or contact a Poison Control Center right away in case of overdose. Call emergency services immediately if the person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Supportive Measures and Risk

There is no known specific antidote. Management involves symptomatic and supportive treatment, focused on the correction of electrolyte disturbances and fluid deficits. Caution is required in patients with impaired hepatic or renal function and elderly patients due to the higher risk of water-electrolyte balance disorders.

Therapeutic Uses of Transipeg

Transipeg is used in situations involving certain distressing symptoms associated with constipation in adults. Its primary purpose is to provide supportive relief for this condition, relevant when supportive symptom management is appropriate.


Therapeutic Focus: Symptom Relief and Functional Support

The medication is commonly used across conditions characterized by periods of heightened symptoms, specifically episodes of occasional constipation. It helps address symptom clusters that often involve physical discomfort and functional strain, and is applied in clinical settings that involve acute or unstable symptom patterns. These scenarios require short-term symptomatic assistance to address symptoms that may temporarily interfere with daily functioning.

The product is considered relevant when supportive symptom management is appropriate for recurrent or episodic manifestations.

By offering supportive relief during these phases, Transipeg assists with maintaining functional stability and contributes to easing the overall symptom load. It is commonly used when symptoms intensify, providing temporary assistance in symptom stabilization and helps patients cope more steadily with difficult episodes.


Key Focus: Symptoms of Physical Discomfort (Transipeg is commonly used for managing symptoms related to physical discomfort that interfere with daily functioning during episodes of constipation.)

Regulatory References

  1. Irish Medicines Board (now HPRA)

Eligibility and Restrictions for Use

Who Can and Cannot Use Transipeg?

Transipeg (which contains Macrogol 3350 and electrolytes) is primarily indicated for the symptomatic treatment of constipation in adults. It is available as a powder for oral solution.


Who Can Use Transipeg

Generally, Transipeg is suitable for use in adults suffering from occasional or chronic constipation. The medication works by increasing the volume of fluid in the colon, which helps to soften the stool and facilitate bowel movements. It is considered a relatively gentle and effective treatment option. Use in children and adolescents should be under the strict guidance of a healthcare professional.


Contraindications (Who Should Not Use Transipeg)

Transipeg is contraindicated and should not be used in individuals with certain gastrointestinal conditions. Consult a doctor immediately if any of the following apply:

Condition Reason for Contraindication
Intestinal perforation or risk of perforation May exacerbate the condition
Severe inflammatory bowel disease (e.g., Crohn’s disease, ulcerative colitis) May lead to complications
Intestinal obstruction or ileus May worsen the blockage
Pain of unknown cause in the abdomen May mask a serious underlying issue
Hypersensitivity to the active substance (Macrogol) Risk of allergic reaction

Individuals with impaired kidney function may need dosage adjustment and should use the medication with caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Transipeg (Macrogol 3350 with electrolytes) primarily through its non-systemic, osmotic action within the digestive tract, as no metabolic or transporter-mediated drug interactions are officially documented.

Pharmacokinetic and Timing Constraints

Interaction Type Official Regulatory Statement
Reduced Absorption Risk Co-administration may result in the transient reduction of intestinal absorption for other oral solid medicinal products, with isolated reports citing decreased efficacy for certain medicines, such as anti-epileptics.
Timing Separation Rule To mitigate the risk of reduced absorption, it is officially recommended to wait at least 2 hours between the intake of Macrogol 3350 and the administration of other solid oral medicinal products.

Physical and Electrolyte Interactions

The Macrogol ingredient is officially documented to physically counteract the function of starch-based food thickeners, resulting in the liquefaction of thickened preparations. This necessitates avoiding their co-mixing.

Population-specific caution exists for patients taking diuretics. Since the osmotic action carries a risk of water/electrolyte imbalance if diarrhoea occurs, regulatory information advises close monitoring for patients on diuretics due to their existing impact on fluid and salt balance.

Mechanism of Action

Osmotic Action and Water Dynamics

The mechanism of Transipeg is centered on physical osmosis within the gut lumen, as its active component, Macrogol 3350, is an inert polymer that is not absorbed into the body. This molecule acts as a hydrophilic solute that physically binds to water, thereby creating an osmotic pressure gradient that opposes the natural passive reabsorption of fluid from the large intestine.


Mechanical Hydration and Propulsive Motility

By forcing water retention, the mechanism achieves increased hydration of the faecal mass and significantly increases its volume. This increased physical bulk mechanically distends the colon wall, activating the natural stretch receptors that indirectly stimulate and enhance peristaltic contractions. This mechanical cascade enhances the overall rate of transit of contents through the colon.


Electrolyte Synergy for Fluid Homeostasis

The formulation includes essential electrolytes that ensure the solution is iso-osmotic (isotonic) when prepared. This synergy establishes an iso-osmotic environment that minimizes the net efflux of water and salts from the systemic circulation into the gut lumen, which preserves systemic fluid and electrolyte equilibrium during the osmotic process.

Dosage and Administration Information

How to Use Transipeg: Administration Guidelines

Transipeg (Macrogol 3350 with electrolytes) is administered according to specific, label-based instructions. The primary administrative domains cover the preparation, route, dosage, frequency, and time-bound nature of the therapy, ensuring standardized use as intended.


Administration Scope

Instruction Component Official Guideline
Route of administration The medicine is taken orally only, following the necessary reconstitution of the powder.
Dosing schedule Adults typically take 1 to 2 sachets daily (referring to the 5.9 g strength). The dosage is flexible within this range and may be adjusted based on individual response, with a maximum daily intake of 2 sachets.
Timing in relation to meals Instructions do not mandate administration with or without food.
Preparation requirements The powder contents must be dissolved in a specific volume of liquid: 100 ml of water per sachet. The resulting solution is intended to be consumed immediately after preparation.
Age-group rules The product is reserved for adults. No specific dose adjustment is necessary for older adults or patients with renal impairment.

Procedural Structure and Duration

The full daily dose is taken as a single intake, which should be administered preferably in the morning. The medication is intended for short-term use only. Instructions state that treatment should be kept as brief as possible and not normally exceed two weeks. The effect of the Macrogol 3350 formulation is generally observed within 24 to 48 hours after the initial dose.

This protocol establishes the standardized approach to using the medicine, defining a clear, single-dose oral regimen taken over a fixed, short duration.

Recent Clinical Evidence

Research Evidence Overview: Understanding the Studies for Transipeg

Evidence for Use in Chronic and Functional Constipation

The most extensive body of research for the active ingredient in Transipeg, Macrogol 3350 with electrolytes, consists of Randomized Controlled Trials (RCTs). These studies involve randomized assignment of participants to different observation groups, including the medicine being studied. These trials are used in research exploring how symptoms change over time for people dealing with ongoing, long-term constipation, which is a condition characterized by fluctuating or episodic manifestations.

In these studies, researchers examined patient outcomes related to functional changes, such as the weekly frequency of complete spontaneous bowel movements (CSBMs) and changes in stool consistency. Studies reported patterns where measured changes in functional measures were observed in the group receiving the medicine, in comparison to the placebo group. Research also examined whether these measurements were sustained during the trial period. Studies monitored outcomes in comparison to other osmotic agents, such as lactulose.

Evidence for Use in Faecal Impaction

Research has also evaluated Macrogol 3350 with electrolytes in the specific scenario of faecal impaction, which is a severe form of constipation involving a physical blockage. The evidence for this specific, short-term application comes largely from comparative studies and open-label studies.

These acute studies monitored outcomes related to resolution measures, focusing on whether the impaction successfully cleared and the time required for this to occur. Research examined short-term symptom changes in the context of the physical obstruction. The evidence described acute, short-term observations and measurements within the dedicated disimpaction phase. Limited information exists regarding long-term functional patterns after the impaction is resolved.

Evidence Quality, Limitations, and Research Gaps

The evidence base is widely considered to be supported by a high level of evidence for the chronic constipation indication, given the number of large RCTs and subsequent systematic reviews. Scientific literature, including meta-analyses, generally classifies the evidence for faecal impaction as moderate.

Research efforts have examined the durability of observed outcomes through trials designed for intermediate and extended observation periods. However, a key research limitation is that follow-up durations were limited in many of the initial major trials, meaning data for very long-term outcomes remains insufficient. Additionally, comparative evidence is lacking against the very newest prescription options.

Key Studies & References

  1. Constipation in children and young people: diagnosis and management (NICE Guideline CG99) - Summary Tables

Frequently Asked Questions (FAQ)

Common questions about Transipeg (FAQ)


Q: Is it possible to use Transipeg for long-term or chronic constipation?

A: Official product information states that treatment for standard constipation should not normally last longer than two weeks. However, official guidelines note that extended use may be authorized by a healthcare provider for severe or resistant chronic constipation, such as those related to underlying medical conditions.


Q: Can using Transipeg lead to electrolyte problems or dehydration?

A: The formulation contains electrolytes specifically to help the body maintain its natural fluid and salt balance while the medicine works. Despite this, diarrhoea is a very common side effect, which can potentially lead to a loss of fluids or electrolytes. Regulatory-linked guidance commonly suggests maintaining sufficient fluid intake.


Q: Why do some people experience abdominal cramping after taking macrogol products?

A: Abdominal pain, abdominal distension (bloating), and flatulence (gas) are common side effects listed in official documents. The medicine works by drawing water into the stool, increasing its volume. This mechanical action can activate the colon’s natural movement (peristalsis), and this process is associated with these common gastrointestinal effects.


Q: Can Transipeg be taken by pregnant women, according to regulatory guidelines?

A: Official regulatory documents indicate that the medicine is not expected to cause effects during pregnancy because the active ingredient, Macrogol 3350, is minimally absorbed by the mother’s body. However, regulatory documents advise that use should be initiated only after a healthcare professional has evaluated the necessity.


Q: Is Transipeg compatible with breastfeeding?

A: According to official product information, Transipeg is considered compatible with breastfeeding. The medicine is virtually unabsorbed systemically, which means it is not expected to pass into breast milk.


Q: Is Transipeg safe for people with known kidney issues?

A: Official guidelines state that no dosage adjustment is necessary for patients with renal (kidney) insufficiency. Despite this, caution is noted for patients with impaired kidney function regarding the potential for fluid and salt balance disorders if they experience severe diarrhoea.


Q: Does Transipeg affect the reliability of hormonal birth control pills?

A: There is a general risk of transiently reduced absorption for any oral solid medication taken concurrently. Additionally, if side effects like severe diarrhoea or vomiting occur, they may impact the efficacy of oral contraceptives.


Q: What does clinical research indicate about the effectiveness of Transipeg?

A: Clinical studies and official information show that Macrogol 3350 with electrolytes is effective in treating chronic constipation and faecal impaction. Results from research indicate an increase in the frequency of normal formed stools.


Q: What should be done if Transipeg does not produce a bowel movement within a few days?

A: The medicine is designed to start working within one to two days. If constipation continues after three days of use, regulatory-linked guidance advises consulting a healthcare professional.


Q: Is it safe to take Transipeg at the same time as other oral medications?

A: Official recommendations state that intake of this medicine should be separated from other solid oral medicinal products by at least two hours. This separation is recommended to mitigate the risk of reduced absorption of the other drug.


Q: Are there specific foods or beverages that should be avoided while using Transipeg?

A: Mixing the macrogol with starch-based food thickeners is advised against in official documents. This is because the medicine can physically counteract their thickening function.


Q: Does Transipeg contain sodium or potassium, and is this a concern for some people?

A: The formulation is confirmed to contain the salts sodium chloride and potassium chloride. This content is included to help maintain the body's natural fluid balance, but it is a factor for patients who are required to control their dietary salt intake.


Q: How is Transipeg different from a stimulant laxative like Senna?

A: Transipeg is classified as an osmotic laxative that works by a physical action—drawing water into the stool to soften it and increase its bulk. This is different from a stimulant laxative, which works by chemically stimulating the nerves and muscles of the gut wall to force movement.


Q: Why do official documents mention that Transipeg may contain electrolytes?

A: The electrolytes are included to ensure that when the Macrogol 3350 passes through the bowel, it is excreted in faecal water without any net gain or loss of the body's natural sodium, potassium, and water levels. This helps maintain internal balance.


Q: Is it possible for the body to become dependent on Transipeg if used daily?

A: Official guidance on laxatives generally states that prolonged use is not usually recommended. This is a standard advisory measure intended to address the common patient concern regarding the risk of dependency or the body becoming reliant on the treatment.


Q: What happens if I forget to take a sachet of Transipeg?

A: Since the medicine is typically taken as needed, if a dose is forgotten, the recommendation is to return to the regular schedule and avoid taking a double dose to make up for the missed one.


Q: Is the sensation of stomach gurgling a sign that Transipeg is starting to work?

A: Regulatory documents list borborygmi (which is stomach rumbling or gurgling) as a common side effect. This is consistent with the medicine's osmotic mechanism, which causes increased fluid and gas activity in the bowel.


Q: Are there any specific lifestyle changes that official guidance recommends alongside taking Transipeg?

A: Regulatory-linked patient guidance frequently recommends complementing the medicine with certain lifestyle measures. These include maintaining a well-balanced diet rich in fiber, drinking plenty of fluids, and exercising regularly.


How should Transipeg be stored and disposed of?

How to Store and Dispose of Transipeg?

The storage and disposal of Transipeg powder are governed by regulatory requirements designed to maintain product quality and ensure safety.

Storage Requirements

  • Temperature and Protection: The powder in sachets must be stored at ambient temperature, specifically below 25°C, and should be protected from excess moisture and direct light.
  • Container and Child Safety: The medicine must be kept in its original container and stored out of the sight and reach of children.
  • Solution Stability: The oral solution has a very limited stability once mixed with water; it must be taken shortly after reconstitution and should not be stored for later use.

Disposal Instructions

Unused or expired Transipeg should not be disposed of in household waste or flushed down the toilet. Regulatory guidelines require consulting a pharmacist or utilizing an official drug take-back program for proper and safe pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Transipeg found in:

A-Z Index: